UniQure暂停法布里病研究高剂量组；Aro公布庞贝病数据。
UniQure pauses higher doses in Fabry study; Aro shares Pompe data
生命科学资讯
生物技术与制药领域的最新动态
杰夫·麦克多诺为NodThera的NLRP3制定宏伟计划；第一三共Enhertu负责人卸任
Geoff McDonough's big plans for NodThera's NLRP3; Enhertu leader steps down at Daiichi
Roivant分拆公司Priovant公布brepocitinib治疗皮肤结节病的二期临床试验数据
Roivant spinout Priovant touts Phase 2 brepocitinib data in cutaneous sarcoidosis
事后直播：深度解析诺和诺德与Hims的GLP-1药物对决
Post-Hoc Live: Analyzing the Novo vs. Hims GLP-1 showdown
Illumina押注医疗健康领域，因特朗普政府削减NIH资金引发行业变局。
Illumina bets on healthcare after Trump administration's NIH funding disruptions
Illumina押注医疗保健客户，因NIH资金中断后寻求新增长点
Illumina bets on healthcare customers after NIH funding disruptions - Endpoints News
FDA局长马卡里质疑Hims公司复合韦戈维药丸计划。
FDA chief Makary takes aim at Hims' compounded Wegovy pill plans
诺和诺德就Wegovy药片起诉Hims面临法律障碍。
Novo's threat to sue Hims over Wegovy pill faces legal hurdle
白宫计划周四推出特朗普处方药计划
White House plans to launch TrumpRx Thursday
Veradermics首席执行官喜迎IPO首日股价飙升122%
Veradermics CEO has a great hair day with 122% pop in IPO
#ISC26：拜耳asundexian在III期试验中将缺血性中风风险降低26%
#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial
百时美施贵宝管线进展引关注，多项数据即将揭晓。
Bristol Myers draws pipeline excitement as several data readouts near
GLP-1药物与超级碗
GLP-1s and the Super Bowl
赛默飞世尔与查尔斯河裁员；药明康德与Vertex签订合同
Thermo Fisher, Charles River workforce cuts; WuXi signs contract with Vertex
远程医疗提供商Hims推出复方版本，挑战诺和诺德减肥药市场。
Telehealth provider Hims goes after Novo's weight loss pill with compounded version
Eikon IPO分析：大型生物科技公司估值大幅下调
Eikon IPO analysis: Big biotech names, big valuation cut
联邦贸易委员会与快捷药方就胰岛素诉讼达成和解。
FTC settles insulin lawsuit with Express Scripts
艾伯维称免疫学重磅药物将成为后修美乐时代增长"主要驱动力"。
AbbVie says immunology blockbusters will be 'main drivers' of growth post-Humira
罕见儿科PRV项目通过政府资助法重新授权至2029年。
Rare pediatric PRV program reauthorized until 2029 via government funding law
葛兰素史克新CEO聚焦更多交易与强化研发管线审查。
GSK’s new CEO eyes more dealmaking, intense pipeline inspection